Immune modulation underpins the anti‐cancer activity of HDAC inhibitors

Abstract excerpt

Aberrant protein acetylation is strongly linked to tumorigenesis, and modulating acetylation through targeting histone deacetylase (HDAC) with small-molecule inhibitors has been the focus of clinical trials. However, clinical success on solid tumours, such as colorectal cancer (CRC), has been limited, in part because the cancer-relevant mechanisms through which HDAC inhibitors act remain largely unknown. Here, we...

Topics

Join the communities discussing this publication.

• Histone Deacetylase Inhibitors Research
• Peptidase Inhibition and Analysis
• Protein Degradation and Inhibitors